Find Novel Neurology Drugs in Preclinical Development

Lead Product(s): SLS-007

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 28, 2020

Details:

Seelos is to begin an in-vivo study delivering SLS-007 by an Adeno-Associated Virus (AAV) vector making the program Seelos’ second gene therapy approach for Parkinson’s Disease (PD).

Lead Product(s): Apilimod mesylate,Rituximab,Atezolizumab

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 16, 2020

Details:

Company receives FDA guidance for pivotal trial design in follicular lymphoma to support accelerated and full approval.

Lead Product(s): Dantrolene Sodium

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Eagle Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement January 13, 2020

Details:

Eagle Pharmaceuticals and the University of Pennsylvania have entered a exclusive worldwide license agreement for the development of dantrolene sodium for treatment of Alzheimer’s disease.

Lead Product(s): BIO-205

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: MPM Capital

Deal Size: $30.0 million Upfront Cash: Undisclosed

Deal Type: Series A Financing January 07, 2020

Details:

The financing will be used to advance the company’s lead program, BIO-205, through human proof-of-concept studies in neuropathic pain as well as to advance its portfolio of A3AR agonists.

Lead Product(s): Cannabis derivatives

Therapeutic Area: Neurology

Highest Development Status: Preclinical Product Type: Undisclosed

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 07, 2020

Details:

Pre-clinical study seeks to determine the impact of cannabis derivatives on mental health conditions.